Japan's Keio University Charts a New Path to Regrowing Nerves After Chronic Spinal Cord Injury

What This Article Covers

Researchers at Keio University in Japan, led by neuroscientist and current International Society for Stem Cell Research (ISSCR) president Hideyuki Okano, have unveiled a new stem cell strategy aimed at one of regenerative medicine's most stubborn targets: chronic, longstanding spinal cord injury. Presented at the ISSCR 2026 Annual Meeting in July, the approach uses “gliogenic” neural stem/progenitor cells engineered to rebuild the support structure around damaged nerve fibers rather than attempting to regrow neurons from scratch — and it is now on a mapped path toward a physician-initiated human trial targeting patients whose injuries are typically considered permanent.

A Different Kind of Cell for a Different Kind of Repair

Most spinal cord stem cell research to date has focused on the subacute phase — the weeks immediately following injury, when the spinal cord environment is still relatively receptive to new neurons. Chronic injury, which affects the vast majority of people living with spinal cord injury worldwide, is a much harder problem: scar tissue has matured, the local environment is hostile to regeneration, and standard neuron-generating stem cell approaches have struggled to show benefit.

Okano's team took a different approach. Instead of transplanting neural stem/progenitor cells designed to become new neurons, they developed “gliogenic” neural stem/progenitor cells (gNS/PCs) — cells directed to become astrocytes and oligodendrocytes, the supporting cells that insulate and maintain existing nerve fibers. The underlying logic is that many chronic spinal cord injury patients retain some demyelinated nerve fibers that have survived the initial trauma but lost their protective myelin sheath. Rather than trying to build new wiring, the gliogenic strategy aims to re-insulate and support the wiring that's already there.

The Evidence So Far

According to the research presented at ISSCR 2026 and reported by the ISSCR, Medical Xpress, and News-Medical.net, clinical-grade gNS/PCs were shown in laboratory conditions to reliably differentiate into astrocytes and oligodendrocytes as designed. When transplanted into animal models of chronic spinal cord injury, the cells “safely promoted behavioral recovery without tumor-like tissue formation while remodeling the injured microenvironment,” according to the ISSCR's summary of the work.

Importantly, this preclinical data builds on real human safety experience. Okano's group has already completed what is described as the world's first clinical study of a related neural stem/progenitor cell approach in patients with subacute spinal cord injury, which “demonstrated a promising safety profile.” That prior human trial — though it targeted a different injury stage — gives the chronic-injury program a head start most first-in-class cell therapies don't have: some existing human tolerability data for the broader cell platform before the new trial even begins.

Why This Matters

Chronic spinal cord injury has long been considered close to untreatable from a regenerative standpoint. Most approved interventions focus on stabilization, rehabilitation, and symptom management rather than restoring lost function. A validated strategy that could safely improve outcomes even years after injury would represent a meaningful expansion of what's medically possible for a patient population that has had very few reasons for optimism on the biological-repair front.

Caveats and What Remains Unproven

This is still, unambiguously, early-stage science. The efficacy data described so far comes from preclinical animal models of chronic injury, not from human trials — the “safe behavioral recovery” reported was observed in transplanted animals, not in people with chronic spinal cord injury. The completed human trial that provides reassuring safety data was conducted in subacute-phase patients, a distinct and generally more treatment-responsive population than the chronic patients the new trial will target. No results in human chronic spinal cord injury patients yet exist, and a strategy proven safe and effective in animal models does not always translate cleanly to humans. The research has also, as of this writing, primarily been shared through conference presentation and institutional/press summaries rather than a fully published, peer-reviewed clinical dataset for the chronic-injury preclinical work specifically.

What's Next

According to the reporting, Keio University plans to launch a physician-initiated clinical trial specifically enrolling patients with chronic, incomplete spinal cord injury who retain demyelinated nerve fibers — the population the gliogenic strategy is designed to help. Patient recruitment is expected to begin in 2027. The stated long-term goal is a standardized cell therapy capable of restoring voluntary movement and autonomic function in patients whose injuries are otherwise considered fixed.

Bottom Line

A Japanese research team has moved a genuinely novel stem cell strategy for chronic spinal cord injury from the lab bench toward a planned human trial, built on a clever insight — repair the insulation around surviving nerve fibers rather than trying to regrow the fibers themselves — and backed by encouraging (if still preclinical) animal data plus reassuring safety experience from a related human trial in a different patient population. It's a hopeful development for a condition that has offered patients very little biological hope, but it remains firmly in the “promising and worth watching” category: no human efficacy data yet exists for chronic injury, and recruitment for that pivotal test isn't expected to begin until 2027.